I-Mab, BCT to work on Arginine Depletion Therapy and Biomarker Study
Drug Discovery | News | 0 Comment | 04 Feb, 2019
I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune disease...Read more
FDA expands Lilly's ALIMTA Label
Drug Discovery | News | 0 Comment | 01 Feb, 2019
Eli Lilly and Companyhas announced that USFDA has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab...Read more
Neurocrine Biosciences collaborates with Voyager Therapeutics
Drug Discovery | News | 0 Comment | 31 Jan, 2019
Neurocrine Biosciences and Voyager Therapeutics has announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy pro...Read more
Pfizer and Lilly announce top-line results of Tanezumab
Drug Discovery | News | 0 Comment | 31 Jan, 2019
Pfizer and Eli Lilly have announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. As per ...Read more
J&J announces USFDA approval of IMBRUVICA
Drug Discovery | News | 0 Comment | 29 Jan, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with obinu...Read more
Basilea announces collaboration with Roche
Drug Discovery | News | 0 Comment | 25 Jan, 2019
Commercial stage biopharma company, Basilea Pharmaceutica has announced that it entered into a collaboration with Roche to explore a combination of Basilea's derazantinib and Roche's PD-L1-...Read more
Wren Therapeutics completes £18M Series A Financing
Drug Discovery | News | 0 Comment | 23 Jan, 2019
UK based biopharma company, Wren Therapeutics focused on drug discovery and development for protein misfolding diseases has announced that it has completed a Series A financing round. The ...Read more
AbbVie provides update on Phase 3 Study of IMBRUVICA
Drug Discovery | News | 0 Comment | 22 Jan, 2019
AbbVie, a research-based global biopharmaceutical company has announced an update on the Phase 3 RESOLVE trial (PCYC-1137) of ibrutinib (IMBRUVICA®) in combination with chemotherapy age...Read more
Everest Medicines signs new deal targeting drug resistance
Drug Discovery | News | 0 Comment | 14 Jan, 2019
Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacter...Read more
Janssen submits application to EMA seeking approval of STELARA
Drug Discovery | News | 0 Comment | 11 Jan, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval o...Read more
Denali Therapeutics announces Phase 1B Study of DNL747
Drug Discovery | News | 0 Comment | 11 Jan, 2019
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases has announced initiation of dosing in a Phase 1b ...Read more
Japan approves Amgen's osteoporosis drug
Drug Discovery | News | 0 Comment | 10 Jan, 2019
Amgen and UCB announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY (romosozumab) for the treatment of osteoporosis in pa...Read more
Daiichi Sankyo receives regulatory approval for hypertension tablets
Drug Discovery | News | 0 Comment | 10 Jan, 2019
Exelixis, Inc. has announced that its partner Daiichi Sankyo Company, Limited received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINN...Read more
Cellular Biomedicine Initiates clinical trial in anti-BCMA CAR-T therapy
Drug Discovery | News | 0 Comment | 09 Jan, 2019
Cellular Biomedicine Group Inc., a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, has announced the initi...Read more
Oculis raises CHF 15.5 million
Drug Discovery | News | 0 Comment | 08 Jan, 2019
Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments recently announced that it has successfully raised a further CHF15.5 million i...Read more
AbbVie and Tizona Therapeutics announce strategic collaboration
Drug Discovery | News | 0 Comment | 04 Jan, 2019
Biopharma company, AbbVie and Biotech company, Tizona Therapeutics has announced that they have entered into a global, strategic collaboration to develop and commercialize CD39-targeted the...Read more
Bristol-Myers Squibb’s Sprycel® tablets now approved for pediatric patients
Drug Discovery | News | 0 Comment | 04 Jan, 2019
Bristol-Myers Squibb Company has announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ®(dasatinib) tablets to include the treatment of...Read more
AstraZeneca announces phase III trials for roxadustat
Drug Discovery | News | 0 Comment | 03 Jan, 2019
AstraZeneca has announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney...Read more